These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9147418)

  • 21. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates.
    Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
    J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects.
    Cohen S; Tuen M; Hioe CE
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):793-806. PubMed ID: 14585210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
    J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.
    Gorny MK; VanCott TC; Hioe C; Israel ZR; Michael NL; Conley AJ; Williams C; Kessler JA; Chigurupati P; Burda S; Zolla-Pazner S
    J Immunol; 1997 Nov; 159(10):5114-22. PubMed ID: 9366441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120.
    Howie SE; Cotton GJ; Heslop I; Martin NJ; Harrison DJ; Ramage R
    FASEB J; 1998 Aug; 12(11):991-8. PubMed ID: 9707171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic identification of T-cell activating epitopes on the human immunodeficiency virus type 1 envelope glycoprotein gp120 in primates immunized with synthetic peptides.
    Eriksson K; Horal P; Svennerholm B; Jeansson S; Vahlne A; Holmgen J; Czerkinsky C
    Vaccine; 1993; 11(8):859-65. PubMed ID: 7689284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
    Keller PM; Arnold BA; Shaw AR; Tolman RL; Van Middlesworth F; Bondy S; Rusiecki VK; Koenig S; Zolla-Pazner S; Conard P
    Virology; 1993 Apr; 193(2):709-16. PubMed ID: 7681612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor.
    Callahan KM; Fort MM; Obah EA; Reinherz EL; Siliciano RF
    J Immunol; 1990 May; 144(9):3341-6. PubMed ID: 1970352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure.
    Kent SJ; Greenberg PD; Hoffman MC; Akridge RE; McElrath MJ
    J Immunol; 1997 Jan; 158(2):807-15. PubMed ID: 8992998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
    Takeshita T; Takahashi H; Kozlowski S; Ahlers JD; Pendleton CD; Moore RL; Nakagawa Y; Yokomuro K; Fox BS; Margulies DH
    J Immunol; 1995 Feb; 154(4):1973-86. PubMed ID: 7530749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.